DB19415ApprovedVaccines
Cemivameran (BNT162b2 Omicron (KP.2)) is COVID-19 mRNA vaccine encoding the viral spike (S) glycoprotein of SARS-CoV-2 Omicron variant lineage KP.2. It is the active ingredient in the 2024-2025 formulation of...
- First approval
- United States, 2024
- Also known as
- BNT162b2 Omicron (KP.2)
Resolves to
Compound
Clinical / RWD
What you can answer from here — as of July 26, 2025
Which companies are running trials of Cemivameran, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account